Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
1018 ISS · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Rituxan | DRUG | Given intravenously once weekly for four weeks. |
| 1018 ISS | DRUG | Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given. |
Inclusion Criteria: * 18 years of age or older * Pathological evidence of CD20+, B-cell follicular non-Hodgkin's lymphoma * Received at least one previous chemotherapy regimen for lymphoma * Hemoglobin \> 8.5 g/dl * WBC \> 2,000/mm3 * ANC \> 1,000/mm3 * Platelet count \> 75,000/mm3 * ECOG performan...
1018 ISS is an investigational therapy being studied in Non-Hodgkin's Lymphoma, specifically B-cell follicular lymphoma. It was evaluated in a Phase 2 study following treatment with Rituxan in patients with this condition. It is not an approved treatment and remains in clinical development.
1018 ISS is being developed by Dynavax Technologies Corporation, which trades under the ticker DVAX. The company sponsored the clinical research evaluating this agent in B-cell follicular lymphoma. Dynavax is the developer associated with this asset.
1018 ISS is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The program enrolled 30 patients in total. As an investigational agent, it has not been approved for any indication.
1018 ISS has been studied in one clinical trial, NCT00251394, titled Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma. This Phase 2 trial was completed, enrolled 30 patients, and was conducted in the United States.
1018 ISS was studied in Non-Hodgkin's Lymphoma, specifically B-cell follicular lymphoma, following Rituxan treatment. The Phase 2 trial NCT00251394 evaluated it in this patient population. It is an investigational agent and is not approved for treating Non-Hodgkin's Lymphoma.